205 related articles for article (PubMed ID: 24041200)
1. Association of thiazolidinediones with gastric cancer in type 2 diabetes mellitus: a population-based case-control study.
Chang SS; Hu HY
BMC Cancer; 2013 Sep; 13():420. PubMed ID: 24041200
[TBL] [Abstract][Full Text] [Related]
2. Risk of bladder cancer in diabetic patients treated with rosiglitazone or pioglitazone: a nested case–control study.
Hsiao FY; Hsieh PH; Huang WF; Tsai YW; Gau CS
Drug Saf; 2013 Aug; 36(8):643-9. PubMed ID: 23797604
[TBL] [Abstract][Full Text] [Related]
3. Risk of stroke with thiazolidinediones: a ten-year nationwide population-based cohort study.
Lu CJ; Sun Y; Muo CH; Chen RC; Chen PC; Hsu CY
Cerebrovasc Dis; 2013; 36(2):145-51. PubMed ID: 24029780
[TBL] [Abstract][Full Text] [Related]
4. Utilization and costs for compliant patients initiating therapy with pioglitazone or rosiglitazone versus insulin in a Medicaid fee-for-service population.
Kalsekar I; Iyer S; Mody R; Rajagopalan R; Kavookjian J
J Manag Care Pharm; 2006 Mar; 12(2):121-9. PubMed ID: 16515370
[TBL] [Abstract][Full Text] [Related]
5. Association between longer therapy with thiazolidinediones and risk of bladder cancer: a cohort study.
Mamtani R; Haynes K; Bilker WB; Vaughn DJ; Strom BL; Glanz K; Lewis JD
J Natl Cancer Inst; 2012 Sep; 104(18):1411-21. PubMed ID: 22878886
[TBL] [Abstract][Full Text] [Related]
6. Association of thiazolidinediones with liver cancer and colorectal cancer in type 2 diabetes mellitus.
Chang CH; Lin JW; Wu LC; Lai MS; Chuang LM; Chan KA
Hepatology; 2012 May; 55(5):1462-72. PubMed ID: 22135104
[TBL] [Abstract][Full Text] [Related]
7. Rosiglitazone Use and the Risk of Bladder Cancer in Patients With Type 2 Diabetes.
Han E; Jang SY; Kim G; Lee YH; Choe EY; Nam CM; Kang ES
Medicine (Baltimore); 2016 Feb; 95(6):e2786. PubMed ID: 26871835
[TBL] [Abstract][Full Text] [Related]
8. The thiazolidinediones rosiglitazone and pioglitazone and the risk of coronary heart disease: a retrospective cohort study using a US health insurance database.
Ziyadeh N; McAfee AT; Koro C; Landon J; Arnold Chan K
Clin Ther; 2009 Nov; 31(11):2665-77. PubMed ID: 20110009
[TBL] [Abstract][Full Text] [Related]
9. Development of heart failure in Medicaid patients with type 2 diabetes treated with pioglitazone, rosiglitazone, or metformin.
Breunig IM; Shaya FT; McPherson ML; Snitker S
J Manag Care Spec Pharm; 2014 Sep; 20(9):895-903. PubMed ID: 25166288
[TBL] [Abstract][Full Text] [Related]
10. Thiazolidinediones, cardiovascular disease and cardiovascular mortality: translating research into action for diabetes (TRIAD).
Bilik D; McEwen LN; Brown MB; Selby JV; Karter AJ; Marrero DG; Hsiao VC; Tseng CW; Mangione CM; Lasser NL; Crosson JC; Herman WH
Pharmacoepidemiol Drug Saf; 2010 Jul; 19(7):715-21. PubMed ID: 20583206
[TBL] [Abstract][Full Text] [Related]
11. Thiazolidinediones and cardiovascular events in patients with type 2 diabetes mellitus: a retrospective cohort study of over 473,000 patients using the National Health Insurance database in Taiwan.
Hsiao FY; Huang WF; Wen YW; Chen PF; Kuo KN; Tsai YW
Drug Saf; 2009; 32(8):675-90. PubMed ID: 19591532
[TBL] [Abstract][Full Text] [Related]
12. Rosiglitazone and pioglitazone utilization from January 2007 through May 2008 associated with five risk-warning events.
Starner CI; Schafer JA; Heaton AH; Gleason PP
J Manag Care Pharm; 2008; 14(6):523-31. PubMed ID: 18693776
[TBL] [Abstract][Full Text] [Related]
13. Rosiglitazone and myocardial infarction in patients previously prescribed metformin.
Dormuth CR; Maclure M; Carney G; Schneeweiss S; Bassett K; Wright JM
PLoS One; 2009 Jun; 4(6):e6080. PubMed ID: 19562036
[TBL] [Abstract][Full Text] [Related]
14. Thiazolidinediones and fractures: evidence from translating research into action for diabetes.
Bilik D; McEwen LN; Brown MB; Pomeroy NE; Kim C; Asao K; Crosson JC; Duru OK; Ferrara A; Hsiao VC; Karter AJ; Lee PG; Marrero DG; Selby JV; Subramanian U; Herman WH
J Clin Endocrinol Metab; 2010 Oct; 95(10):4560-5. PubMed ID: 20631021
[TBL] [Abstract][Full Text] [Related]
15. Thiazolidinediones and the risk of incident strokes in patients with type 2 diabetes: a nested case-control study.
Azoulay L; Schneider-Lindner V; Dell'aniello S; Filion KB; Suissa S
Pharmacoepidemiol Drug Saf; 2010 Apr; 19(4):343-50. PubMed ID: 19998318
[TBL] [Abstract][Full Text] [Related]
16. Association between congestive heart failure and hospitalization in patients with type 2 diabetes mellitus receiving treatment with insulin or pioglitazone: a retrospective data analysis.
Rajagopalan R; Rosenson RS; Fernandes AW; Khan M; Murray FT
Clin Ther; 2004 Sep; 26(9):1400-10. PubMed ID: 15531002
[TBL] [Abstract][Full Text] [Related]
17. Risk of acute myocardial infarction in patients treated with thiazolidinediones or other antidiabetic medications.
Stockl KM; Le L; Zhang S; Harada AS
Pharmacoepidemiol Drug Saf; 2009 Feb; 18(2):166-74. PubMed ID: 19109802
[TBL] [Abstract][Full Text] [Related]
18. Hypoglycaemia with oral antidiabetic drugs: results from prescription-event monitoring cohorts of rosiglitazone, pioglitazone, nateglinide and repaglinide.
Vlckova V; Cornelius V; Kasliwal R; Wilton L; Shakir SA
Drug Saf; 2009; 32(5):409-18. PubMed ID: 19419235
[TBL] [Abstract][Full Text] [Related]
19. Bone loss in diabetes: use of antidiabetic thiazolidinediones and secondary osteoporosis.
Lecka-Czernik B
Curr Osteoporos Rep; 2010 Dec; 8(4):178-84. PubMed ID: 20809203
[TBL] [Abstract][Full Text] [Related]
20. Hospitalised hip fracture risk with rosiglitazone and pioglitazone use compared with other glucose-lowering drugs.
Colhoun HM; Livingstone SJ; Looker HC; Morris AD; Wild SH; Lindsay RS; Reed C; Donnan PT; Guthrie B; Leese GP; McKnight J; Pearson DW; Pearson E; Petrie JR; Philip S; Sattar N; Sullivan FM; McKeigue P;
Diabetologia; 2012 Nov; 55(11):2929-37. PubMed ID: 22945303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]